300147 *ST香雪製藥
按盤價 
6.680 -0.020 (-0.299%)
6.680 -0.020 (-0.299%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 702,776 | -14.09% | 1,595,407 | 1,858,662 | 2,299,288 | 2,187,070 | |
| 減：營業總成本 | 824,704 | -16.85% | 1,970,941 | 2,266,742 | 2,452,474 | 2,575,669 | |
| 其中:營業成本 | 475,214 | -18.72% | 1,159,468 | 1,405,807 | 1,509,521 | 1,643,173 | |
| 財務費用 | 133,166 | -2.16% | 276,612 | 231,011 | 241,471 | 212,510 | |
| 資產減值損失 | (5,485) | -76.18% | (544,408) | (380,109) | (163,342) | (138,578) | |
| 公允價值變動收益 | (669) | -292.15% | (780) | 636 | 2,728 | (12) | |
| 投資收益 | (904) | -224.08% | (835) | (6,000) | (50,640) | 47,329 | |
| 其中：對聯營企業和合營企業的投資收益 | (904) | 284.99% | (984) | (1,343) | (52,159) | 903 | |
| 營業利潤 | (123,243) | -33.09% | (922,598) | (784,525) | (332,716) | (464,142) | |
| 利潤總額 | (237,074) | 9.29% | (1,336,835) | (842,071) | (388,951) | (511,864) | |
| 減：所得稅費用 | 14,618 | 1,889.67% | 33,949 | 19,154 | 12,795 | (7,215) | |
| 淨利潤 | (251,692) | 15.63% | (1,370,785) | (861,224) | (401,746) | (504,648) | |
| 減：非控股權益 | 17,130 | 5.67% | 21,386 | (2,664) | (12,782) | 25,410 | |
| 股東淨利潤 | (268,822) | 14.94% | (1,392,171) | (858,560) | (388,964) | (530,058) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.410 | 17.14% | -2.110 | -1.300 | -0.590 | -0.800 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | -0.951 | -176.56% | -0.545 | 1.595 | 2.911 | 3.637 | |
| 審計意見 # | -- | 带持续经营重大不确定性段落的无保留意见 | 标准的无保留意见 | 保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 27/08/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
